Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd (KZIA) is an innovative global biotechnology company based in Australia. It focuses on bringing new treatment options to patients with cancer. Originally known as Novogen Ltd, the company rebranded as Kazia Therapeutics Limited in November 2017, representing a significant shift in strategic direction.

Kazia Therapeutics’ mission is to take a fresh, innovative approach to maximising the potential of groundbreaking new cancer therapies, aggressively driving them through clinical development and ultimately providing these treatments to patients who are in desperate need. One of Kazia’s most significant assets is its extensive, robust patent portfolio, offering broad protection for its drug candidates and technologies in major markets across the world.

The company is primarily engaged in the development of two investigational drug candidates. The first one is known as paxalisib (formerly GDC-0084), a promising small molecule inhibitor of the PI3K/AKT/mTOR pathway, which is implicated in several types of cancer. Paxalisib is presently undergoing Phase II trials for glioblastoma, the most common and most aggressive form of brain cancer. It has received Orphan Drug Designation from the US Food and Drug Administration (FDA), which provides certain financial and regulatory benefits and is an important step in bringing the drug to market.

The second candidate, EVT801, is a novel small molecule inhibitor of the VEGFR3 signaling pathway acquired from Evotec SE. This drug is in preclinical development for various forms of cancer and has shown great potential in early studies.

The team at Kazia Therapeutics is made up of experienced and dedicated professionals committed to making significant advancements in cancer treatment. They represent a blend of clinical, scientific, operational, and commercial skills uniquely suited to execute the company’s development strategy.

Furthermore, the company has a strong commitment to corporate social responsibility and engaging with the wider community. Its CSR initiatives are based around its internal culture, environmental sustainability and supporting organizations within the oncology sector.

Kazia Therapeutics represents a dynamic and exciting player in the global biotech industry, pushing boundaries and committed to bringing effective solutions to one of the most urgent challenges of human health, cancer. With its innovative approach and promising drug pipeline, KZIA is at the forefront of biotech companies dedicated to cancer treatment.